Aligos Therapeutics, Inc.
ALGSNasdaq
$5.74
↓ -0.2%Jul 17 close · end-of-day
Price
1Y↓ -33.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$59.7M
Enterprise Value
$4.8M
P/E
—
P/S
12.7
P/B
1.9
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$4.7M
Net Income (TTM)
-$90.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-2033.4%
Net Margin
-1919.7%
ROE
-284.1%
ROIC
—
Debt / Equity
—
Net Cash
$54.9M
Return 1Y
-36.5%
Company profile
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB)
- CEO
- Lawrence M. Blatt
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Headquarters
- California
- Website
- www.aligos.com
Earnings
ALGS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.8M↑ +810.0%
Diluted EPS-$2.21↑ +4.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $6.2M | $3.6M | $2.2M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$97.8M | -$128.3M | -$97.6M | -$88.1M | -$89.2M | -$88.0M |
| Net income | -$108.5M | -$128.3M | -$96.0M | -$87.7M | -$131.2M | -$24.2M |
| Diluted EPS | — | — | -$2.25 | -$34.20 | -$20.94 | -$2.45 |
| Operating cash flow | -$74.3M | -$115.7M | -$79.4M | -$79.0M | -$80.7M | -$82.5M |
| Free cash flow | -$76.3M | -$116.6M | -$80.3M | -$79.0M | -$80.9M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | -1423.5% | -2469.0% | -4024.9% |
| Net margin | — | — | — | -1416.2% | -3633.6% | -1106.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.3M | $606,000.00 | $311,000.00 | $965,000.00 | $741,000.00 | $169,000.00 | $2.8M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$26.4M | -$20.1M | -$20.6M | -$19.2M | -$18.6M | -$28.4M | -$21.8M | -$26.9M |
| Net income | $5.1M | -$19.3M | -$82.2M | $43.1M | -$15.9M | -$31.5M | -$19.9M | -$23.0M |
| Diluted EPS | $0.81 | -$3.07 | -$13.10 | -$2.11 | -$1.53 | -$3.04 | $4.23 | -$2.21 |
| Operating cash flow | -$19.5M | -$20.1M | -$18.4M | -$20.9M | -$15.5M | -$24.3M | -$21.7M | -$23.1M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -2489.5% | -1610.5% | -3393.2% | -6187.5% | -1924.0% | -3827.4% | -12907.7% | -951.6% |
| Net margin | 477.0% | -1540.7% | -13556.1% | 13854.7% | -1643.8% | -4256.0% | -11763.9% | -814.1% |
Company news
Jul 6, 2026
- 13d agoALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Dealstocktwits.com
- 14d agoAligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infectionfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.